Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Sci Rep. 2017 Mar 17;7:44727. doi: 10.1038/srep44727.
Because of the pathogenicity and low incidence of avian influenza virus infections in humans, the immune correlates of protection for avian influenza vaccines cannot be determined from clinical studies. Here, we used the ferret model to address this for an avian influenza H5N1 vaccine. Using oil-in-water adjuvants, we generated groups of ferrets with undetectable (geometric mean titer [GMT] < 10), low (GMT = 28.3), or high (GMT > 761.1) hemagglutination-inhibition (HAI) titers to the A/Viet Nam/1203/2004 (H5N1) virus. Ferrets were then challenged with the wild-type virus and disease severity and immunologic parameters were studied. The severity of infection and symptom profile were inversely associated with pre-challenge HAI titers in a dose-dependent manner. A vaccinated ferret with no detectable HAI-antibodies but high flu-specific IgG-antibody titers mounted rapid functional antibodies after infection and experienced milder disease compared to other ferrets in the group. Compared to naïve ferrets, all vaccinated ferrets showed improved cellular immunity in the lungs and peripheral blood. High number of IFNγ CD8- T cells in the airways was associated with early viral clearance. Thus, while neutralizing antibodies are the best correlate of protection, non-neutralizing antibodies can also be protective. This should be taken into consideration in future avian influenza vaccine trials.
由于禽流感病毒在人类中的致病性和低发病率,无法从临床研究中确定禽流感疫苗的保护免疫相关性。在这里,我们使用雪貂模型来解决禽流感 H5N1 疫苗的这个问题。使用油包水佐剂,我们生成了一组雪貂,其血凝抑制(HAI)滴度无法检测到(几何平均滴度 [GMT] < 10)、低(GMT = 28.3)或高(GMT > 761.1),针对 A/Viet Nam/1203/2004(H5N1)病毒。然后,雪貂受到野生型病毒的挑战,并研究了疾病严重程度和免疫参数。感染的严重程度和症状谱与预先挑战的 HAI 滴度呈负相关,呈剂量依赖性。与组中其他雪貂相比,一只未检测到 HAI 抗体但具有高流感特异性 IgG 抗体滴度的接种雪貂在感染后迅速产生功能性抗体,并且疾病较轻。与未接种的雪貂相比,所有接种的雪貂在肺部和外周血中均表现出改善的细胞免疫。气道中大量 IFNγ CD8+ T 细胞与早期病毒清除有关。因此,虽然中和抗体是最好的保护相关性,但非中和抗体也可能具有保护作用。在未来的禽流感疫苗试验中应考虑到这一点。